Clinical Significance and Prognostic Value of Prenatal Diagnosis of Obliteration of the Cavum Septum Pellucidum
Recruiting
Observational Study
Fetal Neurodevelopmental Disorder
Cavum Septum Pellucidum
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 28 Days – 44
- Sex
- Female
- Study type
- Observational
- Participants needed
- 15 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this observational study is to evaluate the incidence of the occurrence of additional abnormalities in fetuses diagnosed with cavum septum pellucidum (CSP) obliteration performed at second-trimester ultrasound, as well as to analyze the postnatal neurological outcome.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pregnant participants with a diagnosis of cavum septum pellucidum obliteration made at second-trimester morphologic ultrasound between 19+0 and 21+6 weeks
* Age \> or = 18 years at the time of outpatient access
* Acquisition of informed consent form, from the patient and minor…
Contacts